{"id":"matching-placebo-tablets","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL942","moleculeType":"Small molecule","molecularWeight":"361.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Matching placebos are used in blinded clinical trials to maintain study integrity by ensuring neither participants nor some study staff know who receives active drug versus control. The placebo is formulated to match the appearance, taste, and administration schedule of the active comparator, allowing for valid efficacy and safety assessment without bias from expectation effects.","oneSentence":"A matching placebo tablet contains inert ingredients designed to be indistinguishable from an active pharmaceutical formulation for use as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:43.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05546554","phase":"PHASE2","title":"Trial of Suvorexant for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT06631287","phase":"PHASE3","title":"Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID","status":"RECRUITING","sponsor":"Wes Ely","startDate":"2024-10-21","conditions":"Long COVID, Sars-CoV-2 Infection, Coronavirus Infections","enrollment":550},{"nctId":"NCT07497087","phase":"PHASE3","title":"A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-06-09","conditions":"Systemic Sclerosis","enrollment":448},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT06450366","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-08","conditions":"Hypercholesterolemia","enrollment":301},{"nctId":"NCT06948097","phase":"PHASE1","title":"Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies","status":"NOT_YET_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2026-04-01","conditions":"Lung Transplantation","enrollment":30},{"nctId":"NCT05142735","phase":"NA","title":"Effects of NAC on Symptoms of CHR Patients","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-01-13","conditions":"Prodromal Schizophrenia","enrollment":90},{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000},{"nctId":"NCT07046494","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder","status":"RECRUITING","sponsor":"Rapport Therapeutics Inc.","startDate":"2025-07-25","conditions":"Bipolar 1 Disorder","enrollment":224},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04140721","phase":"EARLY_PHASE1","title":"Autonomic Determinants of POTS - Pilot 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-08-31","conditions":"Postural Tachycardia Syndrome","enrollment":48},{"nctId":"NCT06280235","phase":"PHASE2","title":"A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-27","conditions":"Depressive Disorder, Major","enrollment":243},{"nctId":"NCT06742723","phase":"PHASE3","title":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-03","conditions":"Chronic Kidney Disease and Hypertension","enrollment":5000},{"nctId":"NCT05501678","phase":"PHASE2","title":"Trial of Diphenhydramine for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT06031844","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-16","conditions":"Coronary Heart Disease","enrollment":24},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Triple Negative Breast Neoplasms","enrollment":137},{"nctId":"NCT07495995","phase":"PHASE2","title":"Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-04-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","enrollment":94},{"nctId":"NCT05540574","phase":"PHASE2","title":"Trial of Zolpidem for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT07225504","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-11","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":1275},{"nctId":"NCT06154447","phase":"PHASE1","title":"Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-12","conditions":"Cystic Fibrosis","enrollment":255},{"nctId":"NCT07497880","phase":"PHASE2","title":"Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity","status":"NOT_YET_RECRUITING","sponsor":"Kailera","startDate":"2026-04-01","conditions":"Obesity, Overweight","enrollment":320},{"nctId":"NCT07498751","phase":"PHASE1","title":"Phase I PK and Safety Study of Ondansetron Inhalation Powder","status":"COMPLETED","sponsor":"Luxena Pharmaceuticals, Inc.","startDate":"2025-03-13","conditions":"Postoperative Nausea and Vomiting","enrollment":24},{"nctId":"NCT07201129","phase":"PHASE3","title":"A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment","status":"RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2026-02-09","conditions":"Nephritis, Lupus, Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT07493265","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy","status":"NOT_YET_RECRUITING","sponsor":"Eisai Inc.","startDate":"2026-03-23","conditions":"Narcolepsy","enrollment":64},{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":"Acute Uncomplicated Diverticulitis","enrollment":100},{"nctId":"NCT07226661","phase":"PHASE2","title":"Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder","status":"RECRUITING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2026-01-19","conditions":"Major Depressive Disorder (MDD)","enrollment":230},{"nctId":"NCT05312879","phase":"PHASE2, PHASE3","title":"Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-03-30","conditions":"Proteinuric Kidney Disease","enrollment":466},{"nctId":"NCT06812078","phase":"PHASE2","title":"A Study of TAK-360 in Adults With Idiopathic Hypersomnia","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-02-07","conditions":"Idiopathic Hypersomnia","enrollment":96},{"nctId":"NCT07144163","phase":"PHASE3","title":"A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-12-11","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":150},{"nctId":"NCT07489612","phase":"PHASE2","title":"QLS1410 in Participants With Uncontrolled Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Hypertension (HTN)","enrollment":260},{"nctId":"NCT07388667","phase":"PHASE1","title":"A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-04","conditions":"Healthy","enrollment":120},{"nctId":"NCT01946204","phase":"PHASE3","title":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-10-14","conditions":"Prostatic Neoplasms","enrollment":1207},{"nctId":"NCT07489495","phase":"PHASE3","title":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-17","conditions":"Carcinoma, Renal Cell","enrollment":758},{"nctId":"NCT06006247","phase":"PHASE2","title":"Early Parkinson's Disease Monotherapy With CVN424","status":"COMPLETED","sponsor":"Cerevance Beta, Inc.","startDate":"2023-09-11","conditions":"Parkinson's Disease","enrollment":64},{"nctId":"NCT06655883","phase":"PHASE3","title":"A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-09","conditions":"Insomnia","enrollment":300},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT05399368","phase":"PHASE2","title":"An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis","status":"TERMINATED","sponsor":"RAPT Therapeutics, Inc.","startDate":"2022-06-07","conditions":"Atopic Dermatitis","enrollment":229},{"nctId":"NCT06637631","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Crohn's Disease","enrollment":260},{"nctId":"NCT07487909","phase":"PHASE1, PHASE2","title":"A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol","status":"COMPLETED","sponsor":"Sen-Jam Pharmaceutical","startDate":"2025-09-30","conditions":"Healthy","enrollment":47},{"nctId":"NCT06698575","phase":"PHASE1","title":"A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2024-12-08","conditions":"Recurrent Genital Herpes Simplex Type 2","enrollment":103},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT07485842","phase":"PHASE4","title":"FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-04","conditions":"Chronic Endometritis","enrollment":300},{"nctId":"NCT07216482","phase":"PHASE3","title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-11","conditions":"Hyperlipidemia","enrollment":975},{"nctId":"NCT07071623","phase":"PHASE3","title":"A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-10","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4580},{"nctId":"NCT06667700","phase":"PHASE3","title":"A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-02","conditions":"Coronavirus Disease (COVID-19)","enrollment":3082},{"nctId":"NCT06641466","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-03-11","conditions":"Menstrual Migraine","enrollment":723},{"nctId":"NCT04300920","phase":"PHASE3","title":"Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial","status":"COMPLETED","sponsor":"Fernando J Martinez","startDate":"2020-12-17","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":202},{"nctId":"NCT07044297","phase":"PHASE3","title":"A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-31","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4390},{"nctId":"NCT05711394","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-05-01","conditions":"Episodic Migraine","enrollment":450},{"nctId":"NCT07355218","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus","enrollment":202},{"nctId":"NCT05421858","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2024-12-11","conditions":"Candidemia, Candidiasis, Invasive","enrollment":450},{"nctId":"NCT07486414","phase":"NA","title":"Efficacy and Safety of NP-2007 on Skin Health","status":"COMPLETED","sponsor":"Hanpoong Nature Pharm Co., Ltd.","startDate":"2022-04-04","conditions":"Skin Aging, Dry Skin","enrollment":84},{"nctId":"NCT07363720","phase":"PHASE3","title":"A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-29","conditions":"Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy","enrollment":88},{"nctId":"NCT05430152","phase":"PHASE2","title":"Low-dose Naltrexone for Post-COVID Fatigue Syndrome","status":"COMPLETED","sponsor":"Luis Nacul","startDate":"2024-01-15","conditions":"Post-Viral Fatigue Syndrome","enrollment":160},{"nctId":"NCT07332481","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":202},{"nctId":"NCT06307652","phase":"PHASE3","title":"Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-12","conditions":"Heart Failure and Impaired Kidney Function","enrollment":4800},{"nctId":"NCT07483489","phase":"PHASE2","title":"A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).","status":"NOT_YET_RECRUITING","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","startDate":"2026-05-01","conditions":"Refractory Chronic Cough","enrollment":180},{"nctId":"NCT05551273","phase":"PHASE2","title":"Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-05","conditions":"Hepatitis B, HIV Infections","enrollment":29},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT07482085","phase":"PHASE3","title":"Efavirenz for the Treatment of Creutzfeldt-Jakob Disease","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-03","conditions":"Creutzfeldt-Jakob Disease","enrollment":246},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT07196501","phase":"PHASE3","title":"A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)","status":"RECRUITING","sponsor":"Neurocrine Biosciences","startDate":"2025-08-18","conditions":"Major Depressive Disorder","enrollment":550},{"nctId":"NCT05529927","phase":"PHASE2","title":"Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Parnassia Addiction Research Centre","startDate":"2026-05","conditions":"Cocaine Use Disorder","enrollment":204},{"nctId":"NCT07268638","phase":"PHASE2","title":"A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)","status":"RECRUITING","sponsor":"Akebia Therapeutics","startDate":"2025-12-03","conditions":"Focal Segmental Glomerulosclerosis","enrollment":60},{"nctId":"NCT05727189","phase":"PHASE1","title":"A Study of Idazoxan in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Terran Biosciences Australia Pty Ltd","startDate":"2023-02-14","conditions":"Healthy","enrollment":150},{"nctId":"NCT07281937","phase":"PHASE2","title":"A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verdiva Bio Dev Limited","startDate":"2025-11-25","conditions":"Obesity, Overweight","enrollment":206},{"nctId":"NCT07118618","phase":"PHASE2","title":"Probenecid Administration for Alcohol Craving and Consumption","status":"RECRUITING","sponsor":"Brown University","startDate":"2026-03-14","conditions":"Alcohol Use Disorder (AUD), Alcohol Consumption, Craving","enrollment":120},{"nctId":"NCT07287189","phase":"PHASE2","title":"Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients","status":"RECRUITING","sponsor":"Satellos Bioscience, Inc.","startDate":"2025-12-08","conditions":"Duchenne Muscular Dystrophy, Duchenne, DMD","enrollment":51},{"nctId":"NCT06366464","phase":"PHASE3","title":"A Study of Pitolisant in Patients With Prader-Willi Syndrome","status":"RECRUITING","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2024-05-28","conditions":"Prader-Willi Syndrome","enrollment":134},{"nctId":"NCT07082738","phase":"PHASE2","title":"A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-27","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1160},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":"Biochemically Recurrent Prostate Cancer","enrollment":985},{"nctId":"NCT05618353","phase":"PHASE4","title":"The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-08-21","conditions":"Coronary Artery Disease","enrollment":700},{"nctId":"NCT07472244","phase":"NA","title":"Does the Development of the Repeated Bout Effect Depend on Oxidative Stress and Inflammation?","status":"RECRUITING","sponsor":"University of Bath","startDate":"2025-09-01","conditions":"Exercise Recovery","enrollment":52},{"nctId":"NCT06619860","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-10-18","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":300},{"nctId":"NCT03748641","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-01-25","conditions":"Castration-Resistant Prostatic Cancer","enrollment":765},{"nctId":"NCT03947216","phase":"PHASE2","title":"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-10-23","conditions":"Parkinson Disease","enrollment":117},{"nctId":"NCT04108208","phase":"PHASE4","title":"A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-17","conditions":"Prostatic Neoplasms","enrollment":75},{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":"Pulmonary Arterial Hypertension","enrollment":935},{"nctId":"NCT07058077","phase":"PHASE2, PHASE3","title":"A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-21","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":153},{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT07218549","phase":"PHASE1","title":"Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use","status":"NOT_YET_RECRUITING","sponsor":"Christopher D. Verrico","startDate":"2026-05-01","conditions":"Opioid Use, Substance Use Disorders, Opioid Analgesia","enrollment":72},{"nctId":"NCT04145674","phase":"PHASE2","title":"A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo","status":"SUSPENDED","sponsor":"Mauro Manconi","startDate":"2022-10-22","conditions":"Restless Legs Syndrome","enrollment":50},{"nctId":"NCT06559306","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-25","conditions":"Depressive Disorder, Major","enrollment":752},{"nctId":"NCT07471867","phase":"PHASE4","title":"Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-03-17","conditions":"Chronic Coronary Syndrome","enrollment":100},{"nctId":"NCT05772546","phase":"PHASE2","title":"Avatrombopag vs. Placebo for CIT in GI Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanny Al-Samkari, MD","startDate":"2023-11-01","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia","enrollment":60},{"nctId":"NCT07466017","phase":"PHASE2","title":"A Study of CS060380 Tablets in Patients With MASH and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-04-14","conditions":"Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity","enrollment":120},{"nctId":"NCT05090904","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2021-11-30","conditions":"Cystic Fibrosis","enrollment":29},{"nctId":"NCT06345404","phase":"PHASE1","title":"Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD","status":"COMPLETED","sponsor":"Corvus Pharmaceuticals, Inc.","startDate":"2024-04-16","conditions":"Atopic Dermatitis","enrollment":82},{"nctId":"NCT05843643","phase":"PHASE3","title":"Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-07-19","conditions":"Systemic Lupus Erythematosus","enrollment":1000},{"nctId":"NCT05359653","phase":"PHASE1, PHASE2","title":"Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-08-01","conditions":"Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive","enrollment":74},{"nctId":"NCT06234501","phase":"NA","title":"Testing the Efficacy of 100mg Vitamin-B6 Daily for Sensory Reactivity in Autism","status":"RECRUITING","sponsor":"University of Reading","startDate":"2024-11-08","conditions":"Autism","enrollment":40},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT06415383","phase":"PHASE1","title":"The Effects of Vitamin B6 Supplementation on Pain Thresholds and Tolerance","status":"COMPLETED","sponsor":"University of Reading","startDate":"2024-05-30","conditions":"Pain","enrollment":43},{"nctId":"NCT05658575","phase":"PHASE2, PHASE3","title":"Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","status":"RECRUITING","sponsor":"Olatec Therapeutics LLC","startDate":"2023-01-06","conditions":"Acute Gout Flare, Gout Attack, Gout Flare","enrollment":300},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT04958031","phase":"PHASE2","title":"A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-06-22","conditions":"Apathy in Dementia","enrollment":41},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":77,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Matching Placebo Tablets","genericName":"Matching Placebo Tablets","companyName":"Vyne Therapeutics Inc.","companyId":"vyne-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":3},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}